医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Hold a Conference Call on Nov 9, 2015 at 4.00 PM IST / 5.30 AM EST

2015年11月07日 AM02:21
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will hold a Conference Call on November 9, 2015 to clarify investors’ queries on the Warning Letter issued by the US FDA dated November 05, 2015.

Audio Webcast

The audio webcast of the call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the call, through Nov 13, 2015. For play back dial in phone No: 022 3065 2322, 022 61813322 and ID: 375#.

Transcript

The transcript of the call will also be available on the Company’s website.

Conference Dial-In Numbers
Primary Number:   +91 22 3960 0616
Secondary Number:   +91 22 6746 5826
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:   6000 1221
Available in – - Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada

Accessible from all major carriers except BSNL/MTNL.

3940 3977

Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune

Accessible from all carriers.

International Toll Free Number:  

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151106005825/en/

CONTACT

Dr. Reddy’s Laboratories
INVESTOR RELATIONS
Kedar
Upadhye, +91-40-66834297
kedaru@drreddys.com
or
MEDIA
RELATIONS

Calvin Printer, +91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险